Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5619 Target Snapshot

DNA repair nuclease/redox regulator APEX1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
36,902Compounds
49Assays
1Approved Drugs
417.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

DNA repair nuclease/redox regulator APEX1 shows clinical signal disease relevance led by cancer. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P27695. Start with cancer, then reuse UniProt P27695 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P27695 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
cancer

DNA repair nuclease/redox regulator APEX1 shows clinical signal disease relevance led by cancer. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include APX-3330. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DNA repair nuclease/redox regulator APEX1 as ChEMBL target CHEMBL5619, mapped to UniProt P27695. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DNA repair nuclease/redox regulator APEX1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5619
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P27695
DNA repair nuclease/redox regulator APEX1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether DNA repair nuclease/redox regulator APEX1 is the right protein anchor across sources, using UniProt P27695 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDNA repair nuclease/redox regulator APEX1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP27695
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDNA repair nuclease/redox regulator APEX1
UniProt AccessionP27695
Component TypeProtein
Sequence Length318 aa

DNA repair nuclease/redox regulator APEX1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as DNA repair nuclease/redox regulator APEX1, mapped to UniProt P27695. Sequence length is 318 aa.

Mapped IDP27695
Review nameDNA repair nuclease/redox regulator APEX1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

DNA repair nuclease/redox regulator APEX1 shows clinical signal disease relevance led by cancer.

Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugAPX-3330
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries clinical signal support. Linked drugs include APX-3330. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
6
Phase II
Assay Mix

Activity Type Distribution

IC50399.0
KI13.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL187266 9.06 Kd 0.88 Preclinical
CHEMBL578390 8.8 Kd 1.6 Clinical
CHEMBL22077 8.0 Kd 10.0 Clinical
CHEMBL275938 7.26 IC50 55.0 Preclinical
CHEMBL4210534 7.26 IC50 55.0 Preclinical
CHEMBL4205402 7.24 IC50 57.0 Preclinical
CHEMBL5653589 7.14 Kd 72.87 Preclinical
CHEMBL22077 7.1 IC50 80.0 Clinical
CHEMBL279014 7.05 Kd 89.0 Clinical
CHEMBL109037 6.96 IC50 110.0 Preclinical
Distribution

pChEMBL Value Distribution

55
5.0
42
5.5
14
6.0
13
6.5
7
7.0
0
7.5
1
8.0
1
8.5
1
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

49
Total Assays
197
Tested Compounds
2
Assay Types
Binding — 45 assays, 197 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 30 85 5.5
cell-based format 9 99 4.9
assay format 6 13 5.9
Functional — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine